SCHEMBL2324686

SCHEMBL2324686

CCOP(=O)(O)CC(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
TSHR P16473 1/20 0.44
GAA P10253 2/20 0.41
F2R P25116 1/20 0.40
P2RX7 Q99572 3/20 0.39
SLC6A2 P23975 3/20 0.38
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 3/20 0.38
MGAM O43451 1/20 0.38
AMY1A P0DUB6 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
JAK2 O60674 1/20 0.38
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
TMEM97 Q5BJF2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322233 0.88 ERCC5 (0.44) ERCC5FEN1TSHRLMNAHPGD
SCHEMBL2324679 0.78 ERCC5 (0.50) TAS1R3TAS1R1TAS1R2ERCC5FEN1
SCHEMBL1549244 0.78 KMT2A (0.48) ERCC5FEN1TSHRGAALMNA
SCHEMBL2324765 0.77 TAS1R3 (0.47) TAS1R3TAS1R1ERCC5FEN1TSHR
SCHEMBL2322162 0.77 KMT2A (0.53) ERCC5FEN1TSHRMEN1KMT2A
SCHEMBL2327750 0.77 NPC1 (0.45) ERCC5FEN1TSHRGAALMNA
SCHEMBL2325440 0.75 NPC1 (0.50) LMNAHPGDKMT2AMAPT
SCHEMBL1549681 0.75 KMT2A (0.42) P2RX7SLC6A2SLC6A4SLC6A3HPGD
SCHEMBL2255346 0.74 ERCC5 (0.61) TAS1R3TAS1R1TAS1R2ERCC5FEN1
SCHEMBL2322050 0.74 POLB (0.43) GAALMNAHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 TAS1R3 3044/4885TAS1R1 1712/4885TAS1R2 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.